We are live on ! Find out more
RXDX

Prometheus Biosciences, Inc. Common Stock
RXDX

Delisted

RXDX was delisted on the 15th of June, 2023.

Back to rankings

2 hedge funds and large institutions have $1.98M invested in Prometheus Biosciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 216 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% less call options, than puts

Call options by funds: $13.6M | Put options by funds: $51.5M

99% less funds holding

Funds holding: 219 → 2 (-217)

100% less capital invested

Capital invested by funds: $4.35B → $1.98M (-$4.35B)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 216

Holders
2
Holders Change
-217
Holders Change %
-99.09%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
216
Calls
$13.6M
Puts
$51.5M
Net Calls
-$37.9M
Net Calls Change
-$118M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$351M
2
BlackRock
BlackRock
New York
-$300M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$292M
4
BC
Boxer Capital
California
-$204M
5
7IH
72 Investment Holdings
Connecticut
-$198M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAA
51
Affinity Asset Advisors
New York
– -$16.1M -150,000 Closed
CC
52
Casdin Capital
New York
– -$16.1M -150,000 Closed
DCMIC
53
Decheng Capital Management III (Cayman)
Cayman Islands
– -$16.1M -150,000 Closed
Bank of New York Mellon
54
Bank of New York Mellon
New York
– -$16.1M -149,996 Closed
CC
55
Commodore Capital
New York
– -$13.6M -127,156 Closed
EA
56
Emerald Advisers
Pennsylvania
– -$13.6M -126,436 Closed
IC
57
Ikarian Capital
Texas
– -$13.5M -125,926 Closed
SIG
58
Senator Investment Group
New York
– -$13.4M -125,000 Closed
SI
59
Sofinnova Investments
California
– -$13.3M -123,842 Closed
VOYA Investment Management
60
VOYA Investment Management
Georgia
– -$13.1M -122,504 Closed
Jennison Associates
61
Jennison Associates
New York
– -$13.1M -122,495 Closed
AG
62
Artal Group
Luxembourg
– -$13.1M -121,756 Closed
SAM
63
Sectoral Asset Management
Quebec, Canada
– -$11.6M -108,090 Closed
EMFAT
64
Emerald Mutual Fund Advisers Trust
Pennsylvania
– -$11.2M -104,825 Closed
American Century Companies
65
American Century Companies
Missouri
– -$10.8M -101,636 Closed
JP Morgan Chase
66
JP Morgan Chase
New York
– -$10.9M -101,586 Closed
PCH
67
Polar Capital Holdings
United Kingdom
– -$9.93M -92,500 Closed
CS
68
Candriam SCA
Luxembourg
– -$8.89M -90,000 Closed
Two Sigma Advisers
69
Two Sigma Advisers
New York
– -$9.55M -89,000 Closed
Citigroup
70
Citigroup
New York
– -$9.2M -85,757 Closed
FCM
71
Frontier Capital Management
Massachusetts
– -$7.11M -66,282 Closed
Amundi
72
Amundi
France
– -$7.17M -65,989 Closed
Russell Investments Group
73
Russell Investments Group
United Kingdom
– -$6.41M -59,697 Closed
Rafferty Asset Management
74
Rafferty Asset Management
New York
– -$6.38M -59,464 Closed
First Trust Advisors
75
First Trust Advisors
Illinois
– -$6.14M -57,258 Closed
1 2
3
4 5

RXDX Hedge Fund Activity: Q2 2023 in Review

2 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q2 2023, worth a combined $1.98M — down 100% from $4.35B a quarter earlier.

Sellers outnumbered buyers: 216 funds closed out of RXDX and 0 opened new positions — a net loss of 216 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was RTW Investments, exiting entirely with an estimated $351M sold.

  • 2 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q2 2023, down from 219 in Q1 2023.
  • Funds reported $1.98M of Prometheus Biosciences, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q2 2023 and 216 closed out, a net change of -216 holders.
  • The largest Prometheus Biosciences, Inc. Common Stock seller in Q2 2023 was RTW Investments, an estimated $351M sold.

Based on aggregated 13F filings for Q2 2023.